BioWorld

May 6, 2009

Amylin Shares Jump on NDA but Drug Class Concerns Linger

San Diego-based Amylin has filed for regulatory approval of once weekly exenatide for diabetes, causing a slight jump in its shares and the shares of its partners, Alkermes and Eli Lilly and Co. (BioWorld Today) Read More

Calistoga's Series B Adds $30M for p110 Delta PI3 Kinase Drugs

Three-Ingredient Cocktail Makes Heart Cells from Stem Cells

Anthera Hits Phase IIb Goals with SPLA2 Inhibitor for Acute ACS

Vernalis Raises £22M Offering Hefty Discount

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...